A promising approach for restoring redox balance in IBD is pharmacological targeting of two signaling pathways of major physiological importance: HIF-1α and NRF2/KEAP1, the critical orchestrators of hypoxia- and oxidative stress-induced cellular response, respectively. Here, HIF1A is linked to inflammatory bowel disease.